Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease

BACKGROUND: In recent years, biological therapies have revolutionized the management of inflammatory bowel disease (IBD); however, they are expensive. The development of biosimilar products has allowed us to reduce healthcare costs and improve patients’ access to these treatments. Although various s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huguet, Jose María, Cortés, Xavier, Bosca-Watts, Marta Maia, Aguas, Marian, Maroto, Nuria, Martí, Lidia, Amorós, Cirilo, Paredes, Jose María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717518/
https://www.ncbi.nlm.nih.gov/pubmed/35071559
http://dx.doi.org/10.12998/wjcc.v9.i36.11285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717518/
https://www.ncbi.nlm.nih.gov/pubmed/35071559
http://dx.doi.org/10.12998/wjcc.v9.i36.11285

Ejemplares similares